Biotechnology Focus Podcast

Welcome to another episode of Biotechnology Focus radio. I am your host – Michelle Currie – here to give you the rundown on the Canadian biotech scene. This week I’ll be discussing how the regenerative medicine community is abuzz, expanding personalized medicine, and the very recent announcement from the Ontario government that brings great news to the life sciences sector.   +++++  The regenerative medicine field, which includes cell and gene therapies (CGTs), is still abuzz with the fall approvals of three CGTs by the U.S. Food and Drug Administration: Novartis’ Kymriah, Gilead/Kite Pharma’s Yescarta and Spark Therapeutics Inc.’s Luxturna.  At the Cell and Gene Therapy World conference in Miami, Florida (January 22-25), many of the talks were either about the approved treatments or congratulating the industry on these significant milestones.  Reni Benjamin, of Raymond James Financial, reminded delegates that the pharmaceutical industry is also feeling confident about cell and gene therapes s. Acqui